AN2 Therapeutics (ANTX) Other Non-Current Assets (2022 - 2026)
AN2 Therapeutics (ANTX) posted quarterly Other Non-Current Assets of $304000.0 for Q1 2025, down 70.85% year-over-year from $1.0 million in Q1 2024, and down 62.19% quarter-over-quarter from $804000.0 in Q4 2024.
Powered by 
Analysis
AN2 Therapeutics (ANTX) Other Non-Current Assets (2022 - 2026) Analysis & Trends
AN2 Therapeutics (ANTX) has reported Other Non-Current Assets for 4 consecutive years, with $304000.0 the latest figure, recorded in Q1 2025.
- In Q1 2025, Other Non-Current Assets fell 70.85% year-over-year to $304000.0; the TTM figure through Mar 2025 stood at $304000.0 (down 70.85% YoY), while the FY2024 annual figure was $804000.0, down 22.91% from the prior year.
- Other Non-Current Assets slipped to $304000.0 in Q1 2025 per ANTX's latest filing, from $804000.0 in the prior quarter.
- Across five years, Other Non-Current Assets topped out at $1.0 million in Q3 2023 and bottomed at $304000.0 in Q1 2025.
- Historically, Other Non-Current Assets has averaged $800000.0 across 4 years, with a median of $720000.0 in 2022.
- Annual changes were most pronounced in 2023 — Other Non-Current Assets jumped 44.86% — and 2025, when it slumped 70.85%.
- AN2 Therapeutics' Other Non-Current Assets stood at $720000.0 in 2022, then surged by 44.86% to $1.0 million in 2023, then slipped by 22.91% to $804000.0 in 2024, then sank by 62.19% to $304000.0 in 2025.
- Business Quant data shows ANTX's Other Non-Current Assets at $304000.0 in Q1 2025, $804000.0 in Q4 2024, and $1.0 million in Q2 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 124.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 618.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 42.45 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 109.58 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 65.13 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 62.96 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 104.44 Mn |
| 10 | AN2 Therapeutics | 262.30 Mn | 262.30 Mn | - | 216,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 216,000.00 |
| Mar 31, 2025 | 304,000.00 |
| Dec 31, 2024 | 804,000.00 |
| Jun 30, 2024 | 1.04 Mn |
| Mar 31, 2024 | 1.04 Mn |
| Dec 31, 2023 | 1.04 Mn |
| Sep 30, 2023 | 1.04 Mn |
| Jun 30, 2023 | 720,000.00 |
| Mar 31, 2023 | 720,000.00 |
| Dec 31, 2022 | 720,000.00 |
| Sep 30, 2022 | 720,000.00 |
| Jun 30, 2022 | 720,000.00 |
| Mar 31, 2022 | 720,000.00 |